Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease

Journal of Urology

Volumn 186, Issue 1, 2011, Pages 91-96

  Arvold, Nils D ^a,b   Chen, Ming Hui ^c   Moul, Judd W ^d   Moran, Brian J ^e   Dosoretz, Daniel E ^f   Baez, Lionel L ^d   Katin, Michael J ^f   Braccioforte, Michelle H ^e   D'Amico, Anthony V ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Prostate Cancer Foundation of Chicago   (United States)

^f 21ST CENTURY ONCOLOGY   (United States)

Author keywords

brachytherapy; mortality; prostatectomy; prostatic neoplasms; risk

Indexed keywords

ANTIANDROGEN; CYTOTOXIC AGENT; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79958278973     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.03.003     Document Type: Article

References (29)

1. M.R. Cooperberg, D.P. Lubeck, and S.S. Mehta Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 2003 S21
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969
3. M.J. Zelefsky, D.A. Kuban, and L.B. Levy Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation Int J Radiat Oncol Biol Phys 67 2007 327
4. J.E. Sylvester, P.D. Grimm, and J.C. Blasko 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience Int J Radiat Oncol Biol Phys 67 2007 57
5. M. Han, A.W. Partin, and C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy The 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
6. C. Giberti, L. Chiono, and F. Gallo Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study World J Urol 27 2009 607
7. J.D. Tward, C.M. Lee, and L.M. Pappas Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis Cancer 107 2006 2392
8. D. Kuban, H. Thames, and L. Levy Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 61 2005 409
9. F.L. Greene Prostate F.L. Greene, D.L. Page, I.D. Fleming, AJCC Cancer Staging Manual 6th ed. 2002 Springer New York 309 316
10. M.R. Cooperberg, J. Cowan, and J.M. Broering High-risk prostate cancer in the United States, 19902007 World J Urol 26 2008 211
11. J.Q. Xu, K.D. Kochanek, and S.L. Murphy Deaths: final data for 2007 National Vital Statistics Reports May 2010 National Center for Health Statistics Hyattsville Web release vol 58 no 19 http://www.cdc.gov/nchs/deaths.htm Accessed August 24, 2010
12. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866
13. A. Agresti An Introduction to Categorical Data Analysis 2nd ed. 2002 John Wiley & Sons New York 16 52
14. M. Hollander, and D.A. Wolfe Nonparametric Statistical Methods 2nd ed. 1999 John Wiley & Sons New York 189 269
15. J.P. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496
16. J.J. Gaynor, E.J. Feuer, and C.C. Tan On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data J Am Stat Assoc 88 1993 400
17. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141
18. Simultaneous inferences and other topics in regression analyses-1 J. Neter, W. Wassermann, and M.H. Kutner Applied Linear Regression Models 1983 R. D. Irwin Homewood, Illinois 150 153
19. S.W. Fine, and J.I. Epstein A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score J Urol 179 2008 1335
20. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial J Urol 181 2009 956
21. M. Bolla, H. van Poppel, and L. Collette Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) Lancet 366 2005 572
22. T. Wiegel, D. Bottke, and U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924
23. B.W. Corn, K. Winter, and M.V. Pilepich Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group Urology 54 1999 495
24. H. Zincke, W. Lau, and E. Bergstralh Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer J Urol 166 2001 2208
25. M.J. Zelefsky, J.A. Eastham, and A.M. Cronin Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix J Clin Oncol 28 2010 1508
26. M.A. Kollmeier, R.G. Stock, and N. Stone Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality Int J Radiat Oncol Biol Phys 57 2003 645
27. A.V. Taira, G.S. Merrick, and R.W. Galbreath Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy Int J Radiat Oncol Biol Phys 76 2010 349
28. A.B. Chen, A.V. D'Amico, and B.A. Neville Provider case volume and outcomes following prostate brachytherapy J Urol 181 2009 113
29. J.P. Ciezki, and E.A. Klein Brachytherapy or surgery? A composite view Oncology (Williston Park) 23 2009 960